FDA Announces Revised Draft Guidance for Hospital and Health System Compounding Under Section 503A of the FD&C Act

Summary

The FDA is releasing a revised draft guidance for industry that outlines how the agency will apply certain provisions of the FD&C Act to human drug products compounded by state-licensed pharmacies within hospital or health systems, addressing stakeholder feedback and providing further clarification on policies regarding hospital and health system compounding.